UnitedHealthcare Individual & Family ACA Marketplace Plans
Clinical Pharmacy Program Guidelines for Antiparkinson Agents

Program	Step Therapy
Medication	Rasagiline (generic Azilect)
Issue Date	9/2020
Pharmacy and Therapeutics Approval Date	11/2022
Effective Date	2/2023

1. Background:

Rasagiline (generic Azilect) is an antiparkinson agent indicated for the treatment of Parkinson's disease as monotherapy or as adjunct therapy in patients taking / not taking levodopa, with or without other Parkinson's Disease drugs.

Step Therapy programs are utilized to encourage the use of lower cost alternatives for certain therapeutic classes. This program requires a member to try selegiline before providing coverage for Rasagiline (generic Azilect).

2. Coverage Criteria[a]:

A. Rasagiline (generic Azilect) will be approved based on the following criterion:

1. History of failure, contraindication, or intolerance to the following (list reason for therapeutic failure, contraindication, or intolerance):

a. selegiline (generic Eldepryl)

Authorization will be issued for 12 months

[a] State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply.

3. Additional Clinical Rules:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.

- Supply limits may be in place

4. References:

1. Rasagiline [package insert]. Overland Park, KS. Teva Neuroscience; April 2021.

Program	Step Therapy – Antiparkinson Agents
Change Control	
Date	Change
10/2016	New program.
1/2017	Administrative change. Clarified applies to Essential PDL only.
10/2017	Annual review. State mandate reference language updated.
10/2018	Annual review. Updated references.
10/2019	Annual review. Administrative changes.
10/2020	Renamed policy to Antiparkinson Agents, revised background, added 90 day supply within the past 120 days language to operationalize step therapy bypass state mandate, and removed brand Azilect as a target drug.
9/2021	Updated references. Updated background to remove automation language.
11/2022	Annual review, no changes to clinical criteria.